CCL2 and prostate carcinoma: The inhibition of CCL2 has been demonstrated in order to improve sensitivity to docetaxel in prostate cancer cell in vitro and the overexpression of CCL2 can enhance cell proliferation in prostate cancer cells that were treated with docetaxel.